Defined Terms Section. Alliance Manager 3.1 Auditor 10.4(c) Bankruptcy Event 13.5 Bankrupt Party 15.13 Claims 11.1 Clinical Supply Agreement 7.1 Commercialization Plan 6.2(a) Commercial Supply Agreement 7.2(a) Competing Program 15.5(b) Confidentiality Agreement 1.20 DMF 5.1(b) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 Global Development Plan 4.3(d) Global Strategy 4.3(d) Global Territory Expansion Opportunity 6.6 GQP Agreement 5.1(b) ICC 14.2 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Initial Purchase Price Payment 8.5(a)(i) JGAAP 1.1 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Kaken Preamble Kaken Housemarks 9.6(b) Kaken Indemnitees 11.1 Kaken Inventions 9.1(c)(ii) Kaken Product Mark 9.6(a) Kaken Sublicense Agreement 2.1(c) Lilly 1.86 Losses 11.1 Defined Terms Section Major Spruce Partner 2.2 Manufacturing Technology Transfer Agreement 7.2(b) NDA 1.56 Non-Bankrupt Party 15.13 Party Preamble Payment 8.9(b) Pharmacovigilance Agreement 5.8 Product Materials 4.6 Reconciliation Amount 8.5(a)(i) Remedial Action 5.9 Right of Reference 5.5 ROFN 6.6 ROFN Exercise Period 6.6 ROFN Exercise Notice 6.6 ROFN Negotiation Period 6.6 ROFN Offer Notice 6.6 Royalty Term 8.4(b) SEC 12.3(c) Spruce Preamble Spruce Indemnitees 11.2 Spruce Inventions 9.1(c)(i) Spruce Partner 2.2 Step-In Rights 9.2(e) Tax Changing Decision 8.9(b) Tax Documents 8.1 Term 13.1 Territory Development Plan 4.2 Territory Expansion Opportunity 6.6 Transfer Price 8.4(a)(i) Working Group 3.5
Defined Terms Section. Action 2.2(e) Affiliate 6.10(a) Agreement Preamble Applicable Procedures 6.10(b) Bank 2.2(b) Burdensome Condition 2.2(d) Closing 1.2(a) Closing Date 1.2(a) Company Preamble Company SEC Reports 2.2(g) Company Subsidiary(ies) 2.2(b) Company’s Knowledge 6.10(f) Contemplated Transactions 2.2(c)(1) DTC 4.2(b) Exchange Act 2.2(d) FDIC 2.2(b) Federal Reserve 2.2(d)
Defined Terms Section. Claims 11.1 Combination Product Dispute 1.55 Commercialization Plan 6.2(a) Competing Program 2.5 Confidentiality Agreement 1.20 CTD 1.17 Development Notice 4.7(b) Development Opt-In Notice 4.7(b) Development Participation Costs Dispute 4.7(b) Development Participation Right 4.7(b) Development Plan 4.2 Dispute 14.1 Effective Date Preamble Enforcing Party 9.4(b) GAAP 1.1 GDP 3.2(a)(vi) GlycoMimetics Preamble GlycoMimetics Indemnitees 11.2 GlycoMimetics Inventions 9.1(d)(i) GlycoMimetics Partner 2.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Initial Development Plan 4.2 Joint Clinical Trial Costs Dispute 4.3(b)(iii) Joint Development Committee (JDC) 3.2(a) Joint Inventions 9.1(d)(iii) Licensed Xxxx 9.6(a) Losses 11.1 Manufacturing Technology Transfer Agreement 7.2 NDA 1.54 Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.7(a) Region 1.7 Remedial Action 5.9 Reversion Background IP 13.6(f) Reversion Collaboration IP 13.6(f) Defined Terms Section [***] [***] Royalty Term 8.4(b) Rules 14.2(a) SEC 12.3(c) Study 4.3(b)(i) Supply Agreement 7.1 Term 13.1 Third Party Infringement Actions 9.5 Step-In Rights 9.2(d) VAT 8.10(c)
Defined Terms Section. 13.1). Clause (e) of the definition of “Eligible Accounts”, as set forth in Section 13.1 of the Loan Agreement is hereby amended and restated in its entirety as follows:
Defined Terms Section. 2014 Notes 6.20 2019 Notes 6.20 2034 Notes 6.20 Acquisition Proposal 6.2(b)(i) Actions 5.1(g)(i) Affected Employees 6.9(a) Affiliate 5.1(a)(i) Agreement Preamble Alternative Acquisition Agreement 6.2(c)(i)(B) Antitrust Law 6.5(e)(vi) Apparel Business 5.1(a)(iv) Applicable Date 5.1(e)(i) Articles of Merger 1.3 Assumption Period 6.14(e)(vii) Bankruptcy and Equity Exception 5.1(c)(i) beneficial ownership 5.2(i) Breach End Date 8.3(b) Business Day 1.2 Bylaws 2.2 Carveout Transactions Recitals Certificate 4.1(a) Change of Recommendation 6.2(c)(ii) Charter 2.1 Chosen Courts 9.5(a) Closing 1.2 Closing Date 1.2 Code 4.2(g) Collective Bargaining Agreements 5.1(m)(i)
Defined Terms Section. 3D Medicines Preamble 3D Medicines Housemarks 9.6(b) 3D Medicines Indemnitees 11.1 3D Medicines Inventions 9.1(c)(ii) 3D Medicines Product Xxxx 9.6(a) 3D Medicines Sublicense Agreement 2.1(c) Accused Party 9.5 Agreement Preamble Alliance Manager 3.1 Aravive Preamble Aravive Indemnitees 11.2 Aravive Inventions 9.1(c)(i) Aravive Licensed Product Opportunity 6.6 Aravive Partner 2.2 Auditor 10.4(c) BLA 1.55 Claims 11.1 Clinical Supply Agreement 7.1(a) Commercialization Plan 6.2(a) Competing Program 15.6(b) Confidentiality Agreement 1.24 Development Plan 4.2 Development Proposal 2.1(a) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 ICC 14.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Losses 11.1
Defined Terms Section. 409A Authorities Section 3.11(e) Adjusted Shareholders’ Equity Section 10.01(f) Agreement Preamble AJCA Section 3.11(e) ALL Section 3.28 Articles of Merger Section 1.02 Bank Section 3.01 Certificate Section 1.06(a) Change in Board Recommendation Section 6.03(b) Claim Section 7.02(a) Closing Section 2.01 Closing Balance Sheet Date Section 6.06 Closing Date Section 2.01 Closing Financial Statements Section 6.06
Defined Terms Section. Accredited Investor...................................................................2.27(a)(iii) Acquisition Transaction...............................................................6.2(d) Agreement.............................................................................Preamble Blue Sky laws.........................................................................2.27(d) Closing...............................................................................1.3
Defined Terms Section. Alliance Manager 2.7 Breaching Party 12.2(a) CDA 9.1 Clinical Operations Sub-Team 2.5(b) Co-Chair 2.3 CRF 2.1(d) CRO 2.6 CRO Agreement 2.1(e) Cure Period 12.2(a) Dispute 13.3(a) ICF 2.1(d) Indemnify 11.1 Infringement 6.3(a) Initial Studies 2.1(a) IRB 2.6 JDC or Joint Development Committee 2.3 JDC Dispute 2.8 Joint Inventions 6.1(e) Joint Patents 6.1(c)(ii) Losses 11.1 Monotherapy Arm 8.11 Monotherapy Study Data 8.11(a) Non-Breaching Party 12.2(a) Non-Prosecuting Party 6.1(c)(ii) Officials 10.9
